01.02.2019Fanny Chen, Olivier Borenstejn

Franklin advises banks on restructuring the institutional ownership of BIOCLINIC

After two recent acquisitions boosted its revenue to €60 million across over 60 sites, BIOCLINIC has organized the exit of Azulis Capital and Galia Gestion, its investors since 2011, and their replacement by Idia Capital Investissement, Amundi PEF, Socadif and Andera Partners (ActoMezz), which bought into the company through a bond investment. BIOCLINIC CEO Philippe Dabi remains the majority shareholder.

The transaction was partly financed by a bank loan arranged by LCL with BNP Paribas, Société Générale, Banque Neuflize OBC, Caisse d’Epargne Ile de France and ZenCap (private debt), advised by FRANKLIN’s Banking & Finance team, led by partner Olivier Borenstejn, assisted by associate Fanny Chen.